Clinical Trial Update: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the efficacy and safety of tisagenlecleucel in high-risk B-cell acute lymphoblastic leukemia patients positive for mini…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Kymriah (tisagenlecleucel)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: B-Cell Acute Lymphoblastic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING